Clinical Trial Detail

NCT ID NCT04145193
Title Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors MedImmune LLC
Indications

colorectal cancer

Therapies

Durvalumab + Fluorouracil + Leucovorin + Oleclumab + Oxaliplatin

Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin

Durvalumab + Fluorouracil + Leucovorin + Monalizumab + Oxaliplatin

Fluorouracil + Leucovorin + Oxaliplatin

Age Groups: adult senior

No variant requirements are available.